Last reviewed · How we verify
Disitamab Vedotin and Gemcitabine
At a glance
| Generic name | Disitamab Vedotin and Gemcitabine |
|---|---|
| Sponsor | Chunguang yang (101937) |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Disitamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing Cisplatin-Ineligible Upper Tract Urothelial Carcinoma (PHASE2)
- Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 (PHASE3)
- RC48 Combined With Chemotherapy in HER2-Positive Advanced Breast Cancer Patients With Prior TOP1i-ADC Failure (PHASE2, PHASE3)
- Probiotics in Advanced Urothelial Carcinoma (PHASE2)
- A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma (PHASE3)
- Study of Disitamab Vedotin Combined With Gemcitabine in Neoadjuvant Treatment of Urothelial Carcinoma (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Disitamab Vedotin and Gemcitabine CI brief — competitive landscape report
- Disitamab Vedotin and Gemcitabine updates RSS · CI watch RSS
- Chunguang yang (101937) portfolio CI